Skip to main content
KBS_Icon_questionmark link-ico


Ashish Patel is a Clinical Senior Lecturer in the School of Cardiovascular Medicine & Sciences at King’s College London and Consultant Vascular and Endovascular Surgeon at Guy’s and St Thomas’ NHS Foundation Trust, London, UK. His British Heart Foundation funded PhD, focussing on monocyte/macrophage biology in tissue remodelling, was awarded in 2013. He completed his Higher Surgical Training in General & Vascular Surgery as a Clinical Academic Lecturer at King’s College London & Guy’s & St Thomas’ NHS Foundation Trust. During this time he received an Academy of Medical Sciences Grant and the Circulation Foundation’s George Davies Visionary Award.

Dr Patel’s research interests are focused on the bench-to-bedside development and translation of novel cardiovascular advanced therapies, particularly for the treatment of peripheral arterial disease. He is an investigator within the BHF Centres of Regenerative Medicine and a Phase I accredited Principal Investigator at Guy’s & St Thomas’ NHS Foundation Trust. His research is funded by the Royal College of Surgeons, Rosetrees Trust, Advanced Therapies Network and the Frances and Augustus Newman Foundation.

Dr Patel is the Principal Investigator of a first in human cell therapy study ROAM-CLI (Retention Of Angiogenic Monocytes in Critical Limb Ischaemia) at the Guy’s and St Thomas’ Biomedical Research Centre. He was awarded the prestigious British Journal of Surgery Prize at the Vascular Society for Great Britain & Ireland Meeting in 2015 and a Global Star and Rising Star Award at the Charing Cross International Symposium in 2018.

As a result of the COVID-19 pandemic, his team instigated a Phase I cell therapy trial using autologous monocytes, engineered to have anti-fibrotic and tissue remodelling properties, for the treatment of patients who develop fibrotic interstitial lung disease after recovery from COVID-19. He is Chief Investigator of this study, the MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic treatment after COVID-19 (NCT04805086) and five patients have been treated with follow-up ongoing.